"Millions of people use injectable drugs like Wegovy to reach a healthier weight. But the weekly injections aren't for everybody or every wallet. That's why experimental pills that could achieve similar results are drawing so much attention. The medicines haven't yet won approval from the Food and Drug Administration, but the first one could get the green light by the end of the year."
"It has the same ingredient semaglutide that's in Wegovy, Ozempic and also in Rybelsus, the company's Type 2 diabetes pill that was approved in 2019. The difference between this new pill and Rybelsus is the dose. There's more semaglutide in the new pill. Novo Nordisk's main competitor is Eli Lilly, which makes Zepbound and Mounjaro. And it's working on an obesity pill, too."
Millions of people use injectable drugs like Wegovy to reach a healthier weight, but weekly injections are not suitable for everyone or every budget. Experimental oral pills that aim to deliver similar weight-loss effects are under review, with the first likely to reach FDA approval by year-end. Novo Nordisk plans a higher-dose semaglutide pill that required an added ingredient to protect it from stomach breakdown for about 30 minutes during absorption. Eli Lilly is developing an oral obesity drug, orforglipron, instead of using tirzepatide. Patients would take the pills daily rather than weekly, raising cost and access questions.
Read at www.npr.org
Unable to calculate read time
Collection
[
|
...
]